The Corporate Reputation of Pharma in Canada, 2019-2020: The Views of 53 Canadian Patient Groups – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “The Corporate Reputation of Pharma in 2019 – The Patient Perspective – Canadian Edition – The Views of 53 Canadian Patient Groups” report has been added to ResearchAndMarkets.com’s offering.

This is the 1st edition of the report series. These 2019 results are drawn from a survey of Canadian patient groups, conducted November 2019 – February 2020.

About the 2019 Survey of Canadian Patient Groups

2019’s 53 respondent Canadian patient groups specialised in 30 different therapy areas.

The 53 Canadian patient groups had the following geographic remits: 6% an international remit; 60% a national remit; 15% regional (an area within Canada); and 19% local.

On Canadian patient-group relationships with pharma

• 87% of the 53 Canadian patient groups responding to the 2019 survey worked with at least one pharma company.

What this Report Contains

Industry-wide analyses: The report examines the issues of importance to Canadian patient groups, including: levels of industry innovation; access to treatments; transparency of the industry; and drug pricing. Analyses are reinforced by extensive feedback from 2019’s respondent Canadian patient groups [found in Appendix I], organised according to the therapy areas of the respondent patient groups.

Individual company analyses: The 18 pharma companies are reviewed by 2019’s 53 respondent Canadian patient groups for overall corporate reputation, and for performance at 12 individual indicators of corporate reputation.

(Read more…)

Key Industry-Wide Findings

Canadian patient groups were generally positive about pharma and its ability to supply drugs useful to patients.

Canadian patient groups, like their peers worldwide, were more positive about the reputation of the pharmaceutical industry in 2019 than in 2018. Some 42% of 2019’s respondent Canadian patient groups described the industry’s corporate reputation as Excellent or Good, compared with 28% saying the same in 2018.

Canadian patient groups clearly appreciate the high-quality products that the pharmaceutical industry can produce. In 2019, as many as 60% of the 53 respondent Canadian patient organisations called the sector Excellent or Good at this activity. The equivalent figure for patient groups worldwide was 53%.

Nevertheless, Canadian patient groups believe that industry could do far more to lower drug prices, improve access to medicines, and have fair pricing policies.

Despite many Canadian patient groups being opposed to the Canadian government’s drug-pricing reform of August 2019, these patient groups also believe that pharma’s pricing arrangements are negatively impacting patients. Just 38% of the 53 respondent Canadian patient groups thought pharma Excellent or Good at ensuring patient access to their medicines; only 10% felt that pharma was Excellent or Good at having fair pricing policies, and just 17% stated that pharma was Excellent or Good at being transparent at drug pricing. Several of the Canadian patient groups emphasised these points with comments.

A regional cancer patient group called for greater transparency, stating: Show figures on pricing in different countries for the same medications, and the methodology behind these pricing decisions.

HIV/AIDS patient group COCQ-SIDA wanted drugs to reflect the cost of development and production, rather than what the market will bear.

Key Company Findings

The results of the Canadian element of the 2019 ‘Corporate Reputation of Pharma’ survey were clearly affected by the battles between the pharmaceutical industry (in particular, specific companies) and Canada’s national and provincial governments – battles about the imposition of new regulations to reduce drug prices, as well as the mandated switching of off-patent biologic drugs to cheaper biosimilars.

Many Canadian patient groups were generally aligned with industry in 2019 against the various government proposals. But the high-profile tussle between pharma and state does seem to have negatively impacted Canadian patient-groups’ views of the corporate reputation of some individual companies in 2019.

Pfizer was ranked overall 1st out of 18 companies for corporate reputation in 2019 by the 40 respondent Canadian patient groups familiar with the company. Pfizer was also ranked 1st by its 24 respondent Canadian patient-group partners.

Boehringer Ingelheim was ranked overall 2nd out of 18 companies for corporate reputation in 2019 by the 24 respondent Canadian patient groups familiar with the company. Boehringer was ranked 4th by its 15 respondent Canadian patient-group partners.

Novartis was ranked overall 3rd out of 18 companies for corporate reputation in 2019 by the 40 respondent Canadian patient groups familiar with the company. Novartis was ranked 2nd by its 26 respondent Canadian patient-group partners.

A note about COVID-19 and this study’s results

COVID-19 should have a relatively limited impact on many of the results of the ‘2019 Corporate-Reputation’ study, because the survey took place (November 2019 to late-February 2020) largely before the crisis became global. However, announcements about COVID-19 by some pharma companies during January and February 2020, may have influenced the views of some patient groups responding to the ‘Corporate-Reputation’ survey during its last two months.

Key Topics Covered

• Executive summary
• Canadian patient-group relationships with pharma, 2019
• Industry-wide findings, 2019
• Rankings of the 18 pharma companies, 2019 (v. 2018) among Canadian patient groups familiar with the companies
• Rankings of the 11 pharma companies, 2019 (v. 2018) among Canadian patient groups that work with the companies
• Profiles of the 18 companies, 2019 (v. 2018)

Profiles of the 18 companies, 2019 v. 2018; charts and tables

• Number of respondent Canadian patient groups claiming familiarity with the company, 2019.
• Number of respondent Canadian patient groups saying that they had a working relationship with the company, 2019.
• Profile of respondent Canadian patient groups familiar with the company, 2019: specialties; geographic remit; and types of relationships.
• Company scores among respondent Canadian patient groups familiar with the company, and which work with the company, for each of the 12 indicators of corporate reputation, 2019.
• Percentage of the respondent Canadian patient groups that work with the company, but which also work with other companies, 2019.
• Overall rankings for the company, according to respondent Canadian patient groups familiar with the company, 2019 v. 2018.
• Overall rankings for the company, according to respondent Canadian patient groups that work with the company, 2019 v. 2018.
• Company rankings for each of the 12 indicators, according to respondent Canadian patient groups familiar, or working, with the company, 2019 v. 2018.
• Snapshot view: where the company sits in the corporate tiers for each of the 12 indicators (in the higher, the middle, or the lower tier), as assessed by respondent Canadian patient groups familiar with the company, 2019.
• Snapshot view: where the company sits in the corporate tiers for each of the 12 indicators (in the higher, the middle, or the lower tier), as assessed by respondent Canadian patient groups that work with the company, 2019.

Companies Mentioned

• AbbVie
• Amgen
• AstraZeneca
• Bayer
• Boehringer Ingelheim
• Bristol Myers Squibb
• Celgene
• Eli Lilly
• Gilead Sciences/Kite Pharma
• GSK
• Janssen
• Merck & Co/MSD
• Novartis
• Pfizer
• Roche
• Sanofi
• Takeda/Shire
• Teva

For more information about this report visit https://www.researchandmarkets.com/r/w3aixu

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900